Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INCB 086550

Next Previous
Search
Drug Profile

INCB 086550

Alternative Names: 86550-106; [14C]-INCB086550; INCB-086550; INCB-86550

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Biosciences Japan; Incyte Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours(In volunteers, In adults) in United Kingdom (PO, Tablet)
  • 03 May 2024 700327195: CTP push: KDM, DevT, HE updated for missing countries, KDM and HE updated for trial termination
  • 26 Mar 2024 Incyte Corporation terminates a phase II trial in Solid tumours in Hungary, Bulgaria, South Korea, Taiwan, Romania, Ukraine (PO) (NCT04629339) (EudraCT2020-000157-27)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top